{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:36:26Z","timestamp":1785368186806,"version":"3.55.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immunotherapy because of its highly immunosuppressive tumor microenvironment. Aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor, has emerged as a key regulator of immune homeostasis and inflammation. However, its systemic immunomodulatory role in PDAC, particularly outside the tumor microenvironment, remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Peripheral blood mononuclear cells (PBMCs) from patients with PDAC and healthy donors were isolated and treated\n                      <jats:italic>ex vivo<\/jats:italic>\n                      with two AHR agonists (Carbidopa and Tapinarof) and one antagonist (BAY 2416964). The samples were stratified into Low and High\/Medium AHR expression groups. Flow cytometry (FC), qPCR, ELISA, Luminex assays, and immunofluorescence imaging were used to evaluate immune checkpoint expression, cytokine secretion, monocyte polarization, and subcellular AHR localization. Overall survival analysis was performed based on the baseline AHR expression levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline AHR expression strongly influenced the immunological effects of AHR modulators. In High\/Medium AHR PBMCs, Carbidopa increased PD-L1 and soluble PD-1 (sPD-1) levels, while IL10 expression was suppressed. In contrast, BAY significantly reduced PD-1 and sPD-1 levels in Low AHR PBMCs, whereas Tapinarof induced the highest IL10 expression. All modulators reduced the proportion of M2-like monocytes, indicating a shift toward less immunosuppressive phenotypes. Nuclear translocation of AHR protein varied across treatments and expression levels. Kaplan\u2013Meier analysis revealed a non-significant trend toward improved overall survival in the High\/Medium AHR group (log-rank p = 0.276).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline AHR expression critically shapes the immune response to pharmacological modulation in PBMCs from PDAC patients. These findings suggest that AHR profiling may serve as a clinically relevant biomarker for stratifying patients and guiding personalized immunotherapy approaches for PDAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1655258","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:15:25Z","timestamp":1763619325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Arenida","family":"Bartkeviciene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldona","family":"Jasukaitiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zievyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ivanauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabija","family":"Stachneviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelija","family":"Jenceviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Karvelyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Stukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Sikarske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiva","family":"Urboniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toivo","family":"Maimets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristaps","family":"Jaudzems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astra","family":"Vitkauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antanas","family":"Gulbinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilvinas","family":"Dambrauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"216636","DOI":"10.1016\/j.canlet.2024.216636","article-title":"Precision treatment of pancreatic ductal adenocarcinoma","volume":"585","author":"Wei","year":"2024","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","article-title":"Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept","volume":"43","author":"Luo","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-024-00372-5","article-title":"Genetic and other risk factors for pancreatic ductal adenocarcinoma (PDAC)","volume":"23","author":"Jacobs","year":"2024","journal-title":"Fam Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1386699","article-title":"Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments","volume":"14","author":"Bugazia","year":"2024","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279001","article-title":"Notch signaling regulates vasculogenic mimicry and promotes cell morphogenesis and the epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma","volume":"17","author":"Benjakul","year":"2022","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107508","DOI":"10.1016\/j.intimp.2021.107508","article-title":"Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview","volume":"95","author":"Panchal","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/cells9030555","article-title":"Cancer stem cells: devil or savior\u2014Looking behind the scenes of immunotherapy failure","volume":"9","author":"Castagnoli","year":"2020","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/cancers16112101","article-title":"Targeting neoantigens in pancreatic ductal adenocarcinoma","volume":"16","author":"Singh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-2116","article-title":"PD-1\/PD-L1 expression in pancreatic cancer and its implication in novel therapies","volume":"94","author":"Mucileanu","year":"2021","journal-title":"Med Pharm Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28358","article-title":"PD\u20101\/PD\u2010L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J Cell Physiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09981-3","article-title":"Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance","volume":"40","author":"Heumann","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S221340","article-title":"The role of PD-1\/PD-L1 axis in treg development and function: implications for cancer immunotherapy","volume":"12","author":"Cai","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1601479","article-title":"SALL4-mediated upregulation of exosomal miR-146a-5p drives T-cell exhaustion by M2 tumor-associated macrophages in HCC","volume":"8","author":"Yin","year":"2019","journal-title":"Oncoimmunology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.3390\/ijms25105490","article-title":"Immunomodulatory precision: A narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment","volume":"25","author":"Qiu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315443","article-title":"Overcoming immune evasion in pancreatic cancer: the combination matters","volume":"67","author":"Michl","year":"2018","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","article-title":"Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity","volume":"55","author":"Hezaveh","year":"2022","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/ijms20051016","article-title":"The prognostic impact of the aryl hydrocarbon receptor (AhR) in primary breast cancer depends on the lymph node status","volume":"20","author":"Jeschke","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/cancers12010145","article-title":"The aryl hydrocarbon receptor is expressed in thyroid carcinoma and appears to mediate epithelial-mesenchymal-transition","volume":"12","author":"Moretti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2730-3","article-title":"Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma","volume":"137","author":"Talari","year":"2018","journal-title":"J Neurooncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1375905","article-title":"The aryl hydrocarbon receptor as a tumor modulator: mechanisms to therapy","volume":"14","author":"Chaudhry","year":"2024","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.15171\/mejdd.2018.126","article-title":"An increased level of aryl hydrocarbon receptor in patients with pancreatic cancer","volume":"11","author":"Masoudi","year":"2018","journal-title":"Middle East J Dig Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-019-00535-5","article-title":"Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2\/PGE2\/STAT3 axis","volume":"14","author":"Zhu","year":"2020","journal-title":"J Cell Commun Signal"},{"key":"B26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/biology9120434","article-title":"Prostaglandin E2 and cancer: insight into tumor progression and immunity","volume":"9","author":"Finetti","year":"2020","journal-title":"Biol (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3390\/cancers15184639","article-title":"Association between AHR expression and immune dysregulation in pancreatic ductal adenocarcinoma: insights from comprehensive immune profiling of peripheral blood mononuclear cells","volume":"15","author":"Bartkeviciene","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"188335","DOI":"10.1016\/j.bbcan.2019.188335","article-title":"The role of AhR in transcriptional regulation of immune cell development and function","volume":"1873","author":"Trikha","year":"2020","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cancers16030472","article-title":"The aryl hydrocarbon receptor: impact on the tumor immune microenvironment and modulation as a potential therapy","volume":"16","author":"Griffith","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00430-8","article-title":"AHR in the intestinal microenvironment: safeguarding barrier function","volume":"18","author":"Stockinger","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007495","article-title":"Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy","volume":"11","author":"Kober","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.3390\/ijms22115736","article-title":"Hijacked immune cells in the tumor microenvironment: molecular mechanisms of immunosuppression and cues to improve T cell-based immunotherapy of solid tumors","volume":"22","author":"Balta","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.06.002","article-title":"Two likely targets for the anti-cancer effect of indole derivatives from cruciferous vegetables: PI3K\/Akt\/mTOR signalling pathway and the aryl hydrocarbon receptor","volume":"46","author":"Popolo","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00949-8","article-title":"The cancer-immune dialogue in the context of stress","volume":"24","author":"Ma","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.12701\/yujm.2021.01312","article-title":"An update on immunotherapy with PD-1 and PD-L1 blockade","volume":"38","author":"Koh","year":"2021","journal-title":"Yeungnam Univ J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1099811","article-title":"Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells","volume":"13","author":"Jin","year":"2023","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbcan.2013.05.001","article-title":"Role of aryl hydrocarbon receptor in cancer","volume":"1836","author":"Feng","year":"2013","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/ijms22020757","article-title":"The landscape of ahR regulators and coregulators to fine-tune ahR functions","volume":"22","author":"Gargaro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827921","article-title":"Biological characteristics and clinical significance of soluble PD-1\/PD-L1 and exosomal PD-L1 in cancer","volume":"13","author":"Niu","year":"2022","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18311","article-title":"Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32733","article-title":"NO \u2022 \/RUNX3\/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer","volume":"146","author":"Wang","year":"2020","journal-title":"Int J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","article-title":"Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review","volume":"154","author":"Silverberg","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1466767","article-title":"Single-cell transcriptome analysis identifies a novel tumor-associated macrophage subtype predicting better prognosis in pancreatic ductal adenocarcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.607209","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming","volume":"8","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq8122","article-title":"Identification of VISTA regulators in macrophages mediating cancer cell survival","volume":"10","author":"Abdrabou","year":"2024","journal-title":"Sci Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.155","article-title":"Sex-dependent differences in the stress mitigating and antidepressant effects of selective aryl hydrocarbon receptor modulators","volume":"319","author":"Madison","year":"2022","journal-title":"J Affect Disord"},{"key":"B50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12958-025-01401-3","article-title":"The aryl hydrocarbon receptor: a new frontier in male reproductive system","volume":"23","author":"Bustani","year":"2025","journal-title":"Reprod Biol Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20170728","article-title":"Carbidopa: a selective Ah receptor modulator (SAhRM)","volume":"474","author":"Safe","year":"2017","journal-title":"Biochem J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20170583","article-title":"Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy","volume":"474","author":"Ogura","year":"2017","journal-title":"Biochem J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"116798","DOI":"10.1016\/j.bcp.2025.116798","article-title":"Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells","volume":"233","author":"Stukas","year":"2025","journal-title":"Biochem Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:15:26Z","timestamp":1763619326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2025.1655258"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1655258","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1655258"}}